This compound is supplied for in-vitro and preclinical research only. It is not a medicinal product. It is not approved for human or veterinary use in any jurisdiction. No therapeutic, medicinal, cosmetic, or performance-enhancement claims are made or implied. By proceeding to inquire, you confirm you are an adult researcher acquiring this compound within your own research framework. Full terms on the Research Use Only page.
Selank
10 mg freeze-dried vial, synthetic tuftsin analogue
Compound specifications, chemistry, and storage.
Technical specifications
Specimen format| Compound name | Selank |
| Also known as | Tuftsin analogue, neurotropic peptide, TKPRPGP |
| CAS number | 129954-34-3 |
| PubChem CID | 11765603 → |
| InChI Key | Reference InChI Key on COA |
| SMILES | Reference SMILES on COA |
| Empirical formula (Hill notation) | C33H57N11O9 |
| Molecular weight | 751.86 g/mol (monoisotopic mass: 751.43) |
| Salt form | Acetate (default) |
| Counter-ion content | Quantified per batch on COA. Custom salt forms (chloride, ammonium, TFA) available on quote. |
| Sequence (1-letter) | TKPRPGP |
| Sequence (3-letter) | Thr-Lys-Pro-Arg-Pro-Gly-Pro |
| Length | 7 amino acids |
| Weight basis | Gross weight per industry standard. Net peptide content quantified on batch COA. |
| Quantity per vial | 10 mg |
| Format | Freeze-dried white powder or thin film, sealed under inert atmosphere. Why does the vial look empty? |
| Appearance | White freeze-dried cake or powder. May also appear as a thin film on the vial wall. |
| Solubility | Water soluble, reconstituted with bacteriostatic water (1 to 2 ml typical) |
| Solution colour | Clear and colourless when correctly reconstituted |
| Purity (HPLC) | Specification ≥98.5%, tested before listing |
| Identity confirmation | LC-MS, batch-specific spectrum on COA |
| Endotoxin (LAL) | Within Ph. Eur. specification, batch report on COA |
| Storage (freeze-dried) | 2 to 8 degrees Celsius, sealed, protected from light. Avoid thermal cycling. |
| Storage (reconstituted) | 2 to 8 degrees Celsius. Use within 4 to 6 weeks. Avoid repeated freeze-thaw. |
| Shelf life | 24 months from synthesis date when storage conditions are maintained |
| Country of synthesis | EU partner facility, Ph. Eur. methodology references |
| Application | In-vitro and preclinical research only. Not for human or veterinary use. |
A synthetic tuftsin analogue, and what the published research says about it.
Selank is a synthetic seven-amino-acid analogue of the immunomodulatory peptide tuftsin, developed by the Institute of Molecular Genetics in Moscow. Published preclinical and clinical research, predominantly Russian-language, has investigated the peptide’s reported anxiolytic, neurotropic, and cognition-modulating activity through GABAergic and serotonergic signalling pathways. The sections below summarise what the published research investigates, what Cresten supplies, and what the certificate of analysis confirms.
Where Selank comes from.
Selank is a synthetic seven-amino-acid peptide developed at the Russian Academy of Medical Sciences in the 1990s. The compound is a synthetic analogue of the natural tetrapeptide Tuftsin, a four-amino-acid sequence (Thr-Lys-Pro-Arg) corresponding to residues 289-292 of the immunoglobulin G heavy chain. The Selank sequence extends the Tuftsin tetrapeptide with three additional residues at the C-terminus, producing the seven-residue compound that is the subject of the published research.
The peptide is built by standard Fmoc solid-phase peptide synthesis, purified by reversed-phase HPLC, and freeze-dried. The sequence extension over Tuftsin was designed to slow plasma degradation, which is rapid for the parent tetrapeptide. The modified form retains the Tuftsin pharmacophore at the N-terminus while extending the half-life sufficiently for practical research use.
PubMed lists roughly 50 papers mentioning Selank or TP-7 as of 2026, with the great majority published by Russian research groups and translated into English. The research is concentrated in central-nervous-system pharmacology, animal models of anxiety-related behaviour, GABA-receptor modulation in cell culture, and a small number of human pilot studies. Accredited replication outside the original research groups is limited in the published literature.
What the research looks at.
Selank mechanism research starts from the central nervous system. Studies have looked at the peptide in animal models of anxiety-related behaviour, with elevated-plus-maze and open-field paradigms commonly used as endpoints. The published literature describes effects in the direction of reduced anxiety-related behaviour against vehicle controls, with the magnitude varying by experimental design and rodent strain.
A second strand of research has examined the peptide in GABA-receptor modulation contexts in cell culture, with measurements of GABAergic signalling in neuronal cultures exposed to the peptide. The published interpretation is that the compound modulates GABA-pathway signalling without acting as a direct GABA-receptor agonist, distinguishing it pharmacologically from benzodiazepine-class compounds. The molecular details of this modulation remain partial in the literature.
"The peptide is studied as a GABA-pathway modulator that does not act as a direct GABA-receptor agonist, with the molecular details still partial in the literature."
A third line of research has examined cytokine-pathway modulation in cell-culture and animal models, building on the relationship of Selank to the parent Tuftsin tetrapeptide, which has a documented role in immune-cell signalling. Studies have measured cytokine output in cultured immune cells and in animal models of stress-induced immune changes. The literature in this strand is smaller than the central-nervous-system literature.
Where the published research does not go: there are no FDA or EMA approvals for Selank in any indication. The peptide has been used in clinical practice in the Russian Federation but is not approved by Western regulatory agencies. The accredited replication of the central-nervous-system findings outside the original Russian research groups is limited. The compound is supplied as a research compound for laboratory research only.
What the certificate confirms.
Every Cresten batch of Selank ships with a certificate from an analytical lab, against the test panel described on the Methodology page. The certificate that ships with your batch confirms:
The certificate format is shown on the batch verification page.
Where the published research on Selank lives.
PubMed indexes 120+ publications mentioning Selank as of 2026. Cresten does not curate a hand-selected reading list. Compound-specific selections influence which papers researchers find first; the unfiltered query, sortable by date, citation count, study type, and species, is queryable directly on PubMed.
Each result on PubMed links to the original journal record and, where available, full-text or open-access copies. Cresten supplies the compound; the literature is for the researcher to evaluate.
Open the full PubMed query →Opens at pubmed.ncbi.nlm.nih.gov in a new tab. The query string is preserved so you can refine, filter, or export from there.
What this monograph is not
This monograph summarises what the published research looks at regarding Selank mechanism. It is not a therapeutic recommendation. It is not dosing guidance. It is not a clinical protocol. It is not medical advice.
Cresten Labs supplies Selank as a research compound for lab-based research only. The decision to investigate any compound in any research framework is the researcher’s decision, within their own ethical, legal, and methodological boundaries.
Cresten makes no claim about human therapeutic use, no claim about clinical effectiveness, no claim about safety in human use, and no claim that this compound has been reviewed by any regulator for any medical use.
Frequently asked questions about Selank
Common research-protocol and supply questions about Selank, with answers grounded in published peer-reviewed research and Cresten Labs supply practice. All information is for in vitro and preclinical research only.
What is Selank?
Selank is a heptapeptide derived from Tuftsin, a 7-amino-acid peptide (CAS 129954-34-3, molecular weight 751.86 g/mol). Cresten Labs supplies Selank as a freeze-dried vial for in vitro and preclinical research only, with each batch verified at Janoshik Analytical.
What does research suggest Selank does?
Published research investigates Selank for modulating GABAergic and serotonergic pathway signaling and stress-response markers in research models. The compound is studied primarily in anxiolytic activity and stress-response research. Selank is supplied for research use only and is not approved by any regulator for medical use.
What is the typical Selank dosage in published research?
Published Selank dosage in research protocols ranges from 250 to 1500 mcg per administration, administered subcutaneously or intranasally, with daily dosing in stress-response and anxiety-marker research. Cresten Labs publishes the typical Selank protocol ranges as research-protocol references only; this is not dosing guidance for human use.
How do I reconstitute Selank for research?
Standard Selank reconstitution adds 2 mL bacteriostatic water (NaCl preferred) for the 10 mg vial. NaCl bacteriostatic water preferred for the cationic peptide class.
What is the Selank half-life and how is Selank storage handled?
Published research reports Selank systemic half-life at short systemic half-life. Selank storage: lyophilized vial stable at room temperature for shipping; reconstituted solution stored at 2 to 8 °C and used within 28 days. The Cresten certificate of analysis lists the synthesis date, batch identifier, and the storage conditions verified for this specific batch.
Selank vs Semax: how do they compare in research?
In published research comparing Selank vs Semax, Selank and Semax are both Russian-school regulatory peptides that operate on different neurotransmitter pathways; the two are sometimes combined in cognitive research. The two compounds are studied separately and in combination depending on the research question. Cresten Labs supplies both as verified research compounds.
What does research literature report about Selank side effects?
Published Selank research reports the following: preclinical models report tolerability; the cationic structure benefits from NaCl bacteriostatic water for injection. Cresten Labs supplies the compound for research use only; clinical-use side-effect data should be drawn from peer-reviewed clinical trial publications, not from research-vendor pages.
Where to buy Selank in Europe?
Cresten Labs supplies Selank across the EU single market to 16 European countries. Each Selank batch is tested at Janoshik Analytical with the certificate of analysis published on the website before it lists. Selank is sold for in vitro and preclinical research only, not for human or veterinary use.
How is Selank verified at Cresten Labs?
Every Selank batch is tested at Janoshik Analytical in Czech Republic, an third-party peptide-analysis laboratory. Each batch certificate documents HPLC purity, mass-spectrometry identity confirmation, and contamination panels. The certificate publishes with the batch, before it lists.
What is the typical Selank stack in published research?
In published research, the typical Selank stack pairs the compound with Semax. Selank and Semax are both Russian-school regulatory peptides that operate on different neurotransmitter pathways; the two are sometimes combined in cognitive research.